Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Auresine R
- Development stage
- Preclinical
- Lead developer
- Mossakowski Medical Research Institute, Polish Academy of Sciences
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Topical
01
Overview
Auresine R (AurR) is an engineered recombinant enzybiotic (bacteriolytic enzyme) developed by the Mossakowski Medical Research Institute of the Polish Academy of Sciences. It is designed to selectively target and hydrolyze the peptidoglycan cell wall of *Staphylococcus aureus* while sparing beneficial commensal skin bacteria such as *Staphylococcus epidermidis*. By selectively eliminating *S. aureus* and restoring the balance of the skin microbiota, Auresine R is being developed as a topical therapy for inflammatory skin conditions associated with dysbiosis, primarily atopic dermatitis, as well as psoriasis, impetigo, and prurigo nodularis.
- Other names
- AuresineRAurezyna RAurezynaR
02
Targets
PGN (Peptidoglycan)
Beyond the preview
Go deeper on Auresine R.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Auresine R.